{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:28:50Z","timestamp":1697524130002},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T00:00:00Z","timestamp":1277337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2002<\/jats:bold> To evaluate toxicity, response and progression\u2010free survival of single nedaplatin chemotherapy in women with platinum\/taxane\u2010resistant\/refractory epithelial ovarian, tubal and peritoneal cancer.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Seventeen patients with platinum\/taxane\u2010resistant\/refractory epithelial ovarian, fallopian tube or primary peritoneal cancer who were treated with a single nedaplatin regimen at 90\u2003mg\/m<jats:sup>2<\/jats:sup> administration on day 1 of a 28\u2010day cycle in our institution between 2005 and 2007 were retrospectively investigated.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Ten of 17 patients (59%) had measurable disease. Seven patients were evaluated according to cancer antigen (CA) 125 levels. The overall response was 24% (complete response, 2 patients; partial response, 2 patients). Two of these 4 patients had measurable disease. Stable disease and progressive disease was noted in 6 (35%) and 7 (41%) patients. Median progression\u2010free survival was 8\u2003months (range 3\u201311) in patients who responded to therapy and 4\u2003months (range 2\u20136) in patients with stable disease. Mean platinum\u2010free interval due to treatment without using platinum analogues after developing platinum\u2010resistant\/refractory disease was 11\u2003months (range 8\u201312) in patients who responded to nedaplatin regimen and 3\u2003months (range 1\u201311) in patients who did not (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01), whereas mean treatment\u2010free interval was 3\u2003months (range 1\u20135) in responders and 1\u2003month (range 1\u20133) in non\u2010responders, which did not show a significant difference. Grade 4 hematological toxicity was observed in 2 of 17 patients (12%). No grade 3 or 4 non\u2010hematological toxicity occurred. All toxicities were managed on an outpatient basis.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Single nedaplatin treatment for platinum\/taxane\u2010resistant\/refractory ovarian, tubal and peritoneal cancer patients is the candidate of salvage chemotherapy with comparable effectiveness and less toxicity to other approved regimens.<\/jats:p>","DOI":"10.1111\/j.1447-0756.2010.01217.x","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T10:00:09Z","timestamp":1277373609000},"page":"764-768","source":"Crossref","is-referenced-by-count":6,"title":["Single nedaplatin treatment as salvage chemotherapy for platinum\/taxane\u2010resistant\/refractory epithelial ovarian, tubal and peritoneal cancers"],"prefix":"10.1111","volume":"36","author":[{"given":"Tomoko","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.2007.148"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601787"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1193"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5237"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh025"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj296"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.07.011"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.10.013"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.091"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.31588"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2733"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008337103708"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00224-X"},{"key":"e_1_2_5_16_2","first-page":"695","article-title":"Phase II study of 254\u2010S (cis\u2010diammine glycolato platinum) for gynecological cancer","volume":"19","author":"Kato T","year":"1992","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050604"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5140"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/28.5.343"},{"key":"e_1_2_5_20_2","first-page":"885","article-title":"A phase II clinical study of cis\u2010diammine glycolato platinum, 254\u2010S, for cervical cancer of the uterus","volume":"19","author":"Noda K","year":"1992","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh081"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00464-5"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1447-0756.2010.01217.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1447-0756.2010.01217.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:12:17Z","timestamp":1697386337000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1447-0756.2010.01217.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,21]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1447-0756.2010.01217.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1447-0756.2010.01217.x","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,21]]}}}